bioMérieux S.A./€BIM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About bioMérieux S.A.
bioMérieux S.A. is a French company specialized in the field of in vitro diagnostics, operating within the healthcare industry. The company develops, manufactures, and markets diagnostic solutions that are primarily used for detecting disease-causing microorganisms. These solutions include a broad range of products, such as diagnostic tests for infectious diseases, cancer, and cardiovascular diseases, as well as industrial microbiological controls. Founded in 1963 by Alain Mérieux, bioMérieux is headquartered in Marcy-l'Étoile, near Lyon, France. The company has a global presence, serving clients around the world through a network of subsidiaries and distributors. Its competitive strength lies in its extensive product portfolio and commitment to research and development, enabling it to address evolving medical and industrial testing needs.
Ticker
€BIM
Sector
Primary listing
PAR
Employees
14,451
Headquarters
Website
bioMérieux S.A. Metrics
BasicAdvanced
€14B
36.37
€3.17
0.46
€0.90
0.78%
Price and volume
Market cap
€14B
Beta
0.46
52-week high
€142.00
52-week low
€95.19
Average daily volume
74K
Dividend rate
€0.90
Financial strength
Current ratio
2.266
Quick ratio
1.297
Long term debt to equity
8.489
Total debt to equity
12.86
Interest coverage (TTM)
45.70%
Profitability
EBITDA (TTM)
999.5
Gross margin (TTM)
56.27%
Net profit margin (TTM)
9.17%
Operating margin (TTM)
17.08%
Effective tax rate (TTM)
27.18%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
8.23%
Return on equity (TTM)
9.49%
Valuation
Price to earnings (TTM)
36.373
Price to revenue (TTM)
3.305
Price to book
3.45
Price to tangible book (TTM)
4.86
Price to free cash flow (TTM)
30.998
Free cash flow yield (TTM)
3.23%
Free cash flow per share (TTM)
3.72
Dividend yield (TTM)
0.78%
Forward dividend yield
0.78%
Growth
Revenue change (TTM)
8.28%
Earnings per share change (TTM)
-8.61%
3-year revenue growth (CAGR)
6.01%
10-year revenue growth (CAGR)
8.34%
3-year earnings per share growth (CAGR)
-12.06%
10-year earnings per share growth (CAGR)
10.05%
3-year dividend per share growth (CAGR)
1.92%
10-year dividend per share growth (CAGR)
10.44%
Bulls say / Bears say
BioMérieux identified a contraction in the Chinese market as the main driver for lowering its 2025 organic sales growth forecast to 6%–7.5%, a sign of weaker demand in its second-largest emerging market (Reuters).
The company reduced its 2025 full-year organic sales outlook to 6%–7.5% from at least 7%, showing increased downside risk to revenues versus expectations under the GO•28 strategic plan (Reuters).
First-half 2025 net income declined 25% year-on-year to €161 million due to a €146 million partial impairment on the Reveal antimicrobial susceptibility testing technology, underlining execution risks in recent acquisitions (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bioMérieux S.A. stock?
bioMérieux S.A. (BIM) has a market cap of €14B as of September 15, 2025.
What is the P/E ratio for bioMérieux S.A. stock?
The price to earnings (P/E) ratio for bioMérieux S.A. (BIM) stock is 36.37 as of September 15, 2025.
Does bioMérieux S.A. stock pay dividends?
Yes, the bioMérieux S.A. (BIM) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €0.9 and the yield is 0.78%. bioMérieux S.A. has a payout ratio of 0% on a trailing twelve-month basis.
When is the next bioMérieux S.A. dividend payment date?
The next bioMérieux S.A. (BIM) dividend payment date is unconfirmed.
What is the beta indicator for bioMérieux S.A.?
bioMérieux S.A. (BIM) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.